首页 > 最新文献

Tumour Virus Research最新文献

英文 中文
Development and evaluation of an online continuing education course to increase healthcare provider self-efficacy to make strong HPV vaccine recommendations to East African immigrant families 开发和评估在线继续教育课程,以提高医疗保健提供者的自我效能,向东非移民家庭提出强有力的HPV疫苗建议
IF 4.3 Q1 VIROLOGY Pub Date : 2021-06-01 DOI: 10.1016/j.tvr.2021.200214
SarahAnn M. McFadden , Linda K. Ko , Megha Shankar , Anisa Ibrahim , Debra Berliner , John Lin , Farah B. Mohamed , Fanaye Amsalu , Ahmed A. Ali , Sou Hyun Jang , Rachel L. Winer

Objective

To develop and evaluate an online continuing education (CE) course designed to improve healthcare provider self-efficacy to make strong adolescent HPV vaccine recommendations to East African immigrant families.

Methods

Focus groups with providers and East African immigrant mothers informed course development. Providers serving East African immigrant families were recruited to view the course and complete pre-/post-test and two-month follow-up surveys. Pre-/post differences were compared with paired t-tests.

Results

202 providers completed the course and pre-/post-test; 158 (78%) completed two-month follow-up. Confidence to make strong HPV vaccine recommendations to East African families increased from 68% pre-test to 98% post-test. Confidence to address common parental concerns also increased: safety, 54% pre-test, 92% post-test; fertility, 55% pre-test, 90% post-test; child too young, 68% pre-test, 92% post-test; and pork gelatin in vaccine manufacturing, 38% pre-test, 90% post-test. Two-month follow-up scores remained high (97% for overall confidence, 94%–97% for addressing parental concerns). All pre-/post-test and pre-test/two-month follow-up comparisons were statistically significant (p < 0.05).

Conclusions

The online CE course focused on culturally appropriate strategies for making strong recommendations and addressing specific parental concerns was effective for increasing provider self-efficacy to recommend HPV vaccination to East African families. Similar courses could be tailored to other priority populations.

目的开发和评估在线继续教育(CE)课程,旨在提高医疗保健提供者的自我效能,向东非移民家庭提供强有力的青少年HPV疫苗建议。方法与提供者和东非移民母亲进行焦点小组讨论,了解课程的发展情况。为东非移民家庭提供服务的提供者被招募来观看课程,并完成测试前/测试后和两个月的随访调查。前后差异采用配对t检验比较。结果202名提供者完成了课程和前后测试;158例(78%)完成了2个月的随访。向东非家庭提出强有力的人乳头瘤病毒疫苗建议的信心从检测前的68%增加到检测后的98%。解决家长常见问题的信心也有所增加:安全,测试前为54%,测试后为92%;生育能力,检测前55%,检测后90%;儿童年龄太小,68%为前测,92%为后测;猪肉明胶在疫苗生产中的比例,38%是前测,90%是后测。两个月的随访得分仍然很高(总体信心为97%,解决父母担忧为94%-97%)。所有测试前/测试后和测试前/两个月随访比较均有统计学意义(p <0.05)。结论在线CE课程侧重于文化上适当的策略,以提出强有力的建议和解决父母的具体问题,有效地提高了提供者向东非家庭推荐HPV疫苗接种的自我效能。类似的课程也可以针对其他优先人群。
{"title":"Development and evaluation of an online continuing education course to increase healthcare provider self-efficacy to make strong HPV vaccine recommendations to East African immigrant families","authors":"SarahAnn M. McFadden ,&nbsp;Linda K. Ko ,&nbsp;Megha Shankar ,&nbsp;Anisa Ibrahim ,&nbsp;Debra Berliner ,&nbsp;John Lin ,&nbsp;Farah B. Mohamed ,&nbsp;Fanaye Amsalu ,&nbsp;Ahmed A. Ali ,&nbsp;Sou Hyun Jang ,&nbsp;Rachel L. Winer","doi":"10.1016/j.tvr.2021.200214","DOIUrl":"10.1016/j.tvr.2021.200214","url":null,"abstract":"<div><h3>Objective</h3><p>To develop and evaluate an online continuing education (CE) course designed to improve healthcare provider self-efficacy to make strong adolescent HPV vaccine recommendations to East African immigrant families.</p></div><div><h3>Methods</h3><p>Focus groups with providers and East African immigrant mothers informed course development. Providers serving East African immigrant families were recruited to view the course and complete pre-/post-test and two-month follow-up surveys. Pre-/post differences were compared with paired t-tests.</p></div><div><h3>Results</h3><p>202 providers completed the course and pre-/post-test; 158 (78%) completed two-month follow-up. Confidence to make strong HPV vaccine recommendations to East African families increased from 68% pre-test to 98% post-test. Confidence to address common parental concerns also increased: safety, 54% pre-test, 92% post-test; fertility, 55% pre-test, 90% post-test; child too young, 68% pre-test, 92% post-test; and pork gelatin in vaccine manufacturing, 38% pre-test, 90% post-test. Two-month follow-up scores remained high (97% for overall confidence, 94%–97% for addressing parental concerns). All pre-/post-test and pre-test/two-month follow-up comparisons were statistically significant (p &lt; 0.05).</p></div><div><h3>Conclusions</h3><p>The online CE course focused on culturally appropriate strategies for making strong recommendations and addressing specific parental concerns was effective for increasing provider self-efficacy to recommend HPV vaccination to East African families. Similar courses could be tailored to other priority populations.</p></div>","PeriodicalId":52381,"journal":{"name":"Tumour Virus Research","volume":"11 ","pages":"Article 200214"},"PeriodicalIF":4.3,"publicationDate":"2021-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.tvr.2021.200214","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25417755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 13
Harnessing immunity for therapy in human papillomavirus driven cancers 利用免疫治疗人类乳头瘤病毒驱动的癌症
IF 4.3 Q1 VIROLOGY Pub Date : 2021-06-01 DOI: 10.1016/j.tvr.2021.200212
Peter L. Stern

In persistent high-risk HPV infection, viral gene expression can trigger some important early changes to immune capabilities which act to protect the lesion from immune attack and subsequently promote its growth and ability for sustained immune escape. This includes immune checkpoint-inhibitor ligand expression (e.g. PD-L1) by tumour or associated immune cells that can block any anti-tumour T-cell effectors. While there are encouraging signs of efficacy for cancer immunotherapies including with immune checkpoint inhibitors, therapeutic vaccines and adoptive cell therapies, overall response and survival rates remain relatively low. HPV oncogene vaccination has shown some useful efficacy in treatment of patients with high-grade lesions but was unable to control later stage cancers. To maximally exploit anti-tumour immune responses, the suppressive factors associated with HPV carcinogenesis must be countered. Importantly, a combination of chemotherapy, reducing immunosuppressive myeloid cells, with therapeutic HPV vaccination significantly improves impact on cancer treatment. Many clinical trials are investigating checkpoint inhibitor treatments in HPV associated cancers but response rates are limited; combination with vaccination is being tested. Further investigation of how chemo- and/or radio-therapy can influence the recovery of effective anti-tumour immunity is warranted. Understanding how to optimally deploy and sequence conventional and immunotherapies is the challenge.

在持续的高危HPV感染中,病毒基因表达可引发免疫能力的一些重要早期变化,这些变化可保护病变免受免疫攻击,并随后促进其生长和持续免疫逃逸的能力。这包括肿瘤或相关免疫细胞的免疫检查点抑制剂配体表达(例如PD-L1),可以阻断任何抗肿瘤t细胞效应物。虽然癌症免疫疗法(包括免疫检查点抑制剂、治疗性疫苗和过继性细胞疗法)的疗效有令人鼓舞的迹象,但总体反应和存活率仍然相对较低。HPV癌基因疫苗在治疗高级别病变患者中显示出一些有用的疗效,但无法控制晚期癌症。为了最大限度地利用抗肿瘤免疫反应,必须对抗与HPV致癌相关的抑制因子。重要的是,化疗,减少免疫抑制性骨髓细胞,与治疗性HPV疫苗接种的组合显着提高了对癌症治疗的影响。许多临床试验正在研究HPV相关癌症的检查点抑制剂治疗,但反应率有限;与疫苗接种的结合正在试验中。进一步研究化疗和/或放疗如何影响有效抗肿瘤免疫的恢复是必要的。了解如何优化常规疗法和免疫疗法的部署和排序是一个挑战。
{"title":"Harnessing immunity for therapy in human papillomavirus driven cancers","authors":"Peter L. Stern","doi":"10.1016/j.tvr.2021.200212","DOIUrl":"10.1016/j.tvr.2021.200212","url":null,"abstract":"<div><p>In persistent high-risk HPV infection, viral gene expression can trigger some important early changes to immune capabilities which act to protect the lesion from immune attack and subsequently promote its growth and ability for sustained immune escape. This includes immune checkpoint-inhibitor ligand expression (e.g. PD-L1) by tumour or associated immune cells that can block any anti-tumour T-cell effectors. While there are encouraging signs of efficacy for cancer immunotherapies including with immune checkpoint inhibitors, therapeutic vaccines and adoptive cell therapies, overall response and survival rates remain relatively low. HPV oncogene vaccination has shown some useful efficacy in treatment of patients with high-grade lesions but was unable to control later stage cancers. To maximally exploit anti-tumour immune responses, the suppressive factors associated with HPV carcinogenesis must be countered. Importantly, a combination of chemotherapy, reducing immunosuppressive myeloid cells, with therapeutic HPV vaccination significantly improves impact on cancer treatment. Many clinical trials are investigating checkpoint inhibitor treatments in HPV associated cancers but response rates are limited; combination with vaccination is being tested. Further investigation of how chemo- and/or radio-therapy can influence the recovery of effective anti-tumour immunity is warranted. Understanding how to optimally deploy and sequence conventional and immunotherapies is the challenge.</p></div>","PeriodicalId":52381,"journal":{"name":"Tumour Virus Research","volume":"11 ","pages":"Article 200212"},"PeriodicalIF":4.3,"publicationDate":"2021-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.tvr.2021.200212","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25381822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
Effective HPV vaccination coverage in Australia by number of doses and two-dose spacing: What if one or two doses are sufficient? 澳大利亚有效的HPV疫苗接种覆盖率按剂量数和两剂间隔:如果一剂或两剂就足够了呢?
IF 4.3 Q1 VIROLOGY Pub Date : 2021-06-01 DOI: 10.1016/j.tvr.2021.200216
Megan A. Smith , Karen Winch , Karen Canfell , Julia ML. Brotherton

Background

Initially, three-dose schedules were recommended for vaccines against human papillomavirus (HPV); subsequently recommendations have been updated to a schedule of two doses delivered at least six (minimum five) months apart for those aged <15 years at dose 1. We aimed to re-estimate effective HPV vaccination coverage in Australia, considering reduced-dose schedules and possible one-dose effectiveness. We also aimed to identify which of the three school visits was most commonly missed amongst two-dose only recipients, to inform optimal timing of visits.

Methods

National vaccination register data were used to estimate: i) vaccination coverage at December 2017, either with a complete course (three or two sufficiently-spaced doses (>151 days apart)), or at least one dose; ii) for each birth cohort offered vaccination, the percentage of the initially targeted cohort with a complete course, or at least one dose (reflecting uptake at the time the vaccine was offered); and iii) among two-dose only recipients, the percentage who missed each of three school visits.

Results

Including those with two sufficiently-spaced doses increased end-2017 coverage by 1.3–2.8% points in those vaccinated at school. Including those with at least one dose increased coverage further, by 6.5–9.5% points, mostly due to including those receiving multiple too-closely-spaced doses. One-dose coverage reached 90.9% and 86.9% in females and males respectively born in 2002.

Among those vaccinated at school who received only two doses, it was much more common to miss the first (31.0% females; 32.5% males) or the third visit in the school year (54.6% females; 48.6% males) than the second (14.1% females; 18.8% males).

Conclusions

Including those with two sufficiently-spaced doses has a very modest impact on HPV vaccine coverage in Australia. If receiving at least one dose offers substantial protection, these data suggest that the school-based program is now achieving close to 90% coverage on this measure.

最初,人类乳头瘤病毒(HPV)疫苗推荐采用三剂接种方案;随后,建议更新为15岁人群两次剂量至少间隔6个月(至少5个月),每次剂量为1。我们的目的是重新估计澳大利亚有效的HPV疫苗接种覆盖率,考虑减少剂量计划和可能的单剂量有效性。我们还旨在确定三种学校访问中哪一种在仅两次剂量的接受者中最常错过,以告知最佳访问时间。方法使用国家疫苗接种登记数据来估计:i) 2017年12月的疫苗接种覆盖率,要么是完整疗程(3次或2次足够间隔的剂量(间隔151天)),要么是至少一次剂量;Ii)对于每个提供疫苗接种的出生队列,最初目标队列中完成整个接种过程或至少一次接种的百分比(反映在提供疫苗时的接种情况);第三,在只注射两次疫苗的接受者中,错过三次学校访问的百分比。结果:包括两次足够间隔剂量的人在内,2017年底在学校接种疫苗的覆盖率提高了1.3-2.8%。包括那些至少接受一次剂量的人,覆盖率进一步提高了6.5-9.5%,这主要是由于包括那些接受多次间隔太近的剂量的人。2002年出生的女性和男性的单剂覆盖率分别达到90.9%和86.9%。在那些在学校只接种了两剂疫苗的人中,错过第一剂疫苗的情况更为常见(31.0%的女性;32.5%男性)或在学年内第三次到访(54.6%女性;男性48.6%),女性14.1%;18.8%的男性)。结论:在澳大利亚,包括两次足够间隔的剂量对HPV疫苗覆盖率的影响非常有限。如果至少接种一剂疫苗就能提供实质性的保护,这些数据表明,以学校为基础的项目目前在这一措施上的覆盖率接近90%。
{"title":"Effective HPV vaccination coverage in Australia by number of doses and two-dose spacing: What if one or two doses are sufficient?","authors":"Megan A. Smith ,&nbsp;Karen Winch ,&nbsp;Karen Canfell ,&nbsp;Julia ML. Brotherton","doi":"10.1016/j.tvr.2021.200216","DOIUrl":"10.1016/j.tvr.2021.200216","url":null,"abstract":"<div><h3>Background</h3><p>Initially, three-dose schedules were recommended for vaccines against human papillomavirus (HPV); subsequently recommendations have been updated to a schedule of two doses delivered at least six (minimum five) months apart for those aged &lt;15 years at dose 1. We aimed to re-estimate effective HPV vaccination coverage in Australia, considering reduced-dose schedules and possible one-dose effectiveness. We also aimed to identify which of the three school visits was most commonly missed amongst two-dose only recipients, to inform optimal timing of visits.</p></div><div><h3>Methods</h3><p>National vaccination register data were used to estimate: i) vaccination coverage at December 2017, either with a complete course (three or two sufficiently-spaced doses (&gt;151 days apart)), or at least one dose; ii) for each birth cohort offered vaccination, the percentage of the initially targeted cohort with a complete course, or at least one dose (reflecting uptake at the time the vaccine was offered); and iii) among two-dose only recipients, the percentage who missed each of three school visits.</p></div><div><h3>Results</h3><p>Including those with two sufficiently-spaced doses increased end-2017 coverage by 1.3–2.8% points in those vaccinated at school. Including those with at least one dose increased coverage further, by 6.5–9.5% points, mostly due to including those receiving multiple too-closely-spaced doses. One-dose coverage reached 90.9% and 86.9% in females and males respectively born in 2002.</p><p>Among those vaccinated at school who received only two doses, it was much more common to miss the first (31.0% females; 32.5% males) or the third visit in the school year (54.6% females; 48.6% males) than the second (14.1% females; 18.8% males).</p></div><div><h3>Conclusions</h3><p>Including those with two sufficiently-spaced doses has a very modest impact on HPV vaccine coverage in Australia. If receiving at least one dose offers substantial protection, these data suggest that the school-based program is now achieving close to 90% coverage on this measure.</p></div>","PeriodicalId":52381,"journal":{"name":"Tumour Virus Research","volume":"11 ","pages":"Article 200216"},"PeriodicalIF":4.3,"publicationDate":"2021-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.tvr.2021.200216","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38802429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 7
Human papillomavirus E6 and E7: What remains? 人乳头瘤病毒E6和E7:还剩下什么?
IF 4.3 Q1 VIROLOGY Pub Date : 2021-06-01 DOI: 10.1016/j.tvr.2021.200213
Arushi Vats , Oscar Trejo-Cerro , Miranda Thomas, Lawrence Banks

Decades of research on the human papillomavirus oncogenes, E6 and E7, have given us huge amounts of data on their expression, functions and structures. We know much about the very many cellular proteins and pathways that they influence in one way or another. However, much of this information is quite discrete, referring to one activity examined under one condition. It is now time to join the dots to try to understand a larger picture: how, where and when do all these interactions occur... and why? Examining these questions will also show how many of the yet obscure cellular processes work together for cellular and tissue homeostasis in health and disease.

数十年来对人类乳头瘤病毒致癌基因E6和E7的研究为我们提供了大量关于它们的表达、功能和结构的数据。我们对许多细胞蛋白质和它们以这样或那样的方式影响的途径了解得很多。然而,这些信息大多是离散的,指的是在一种条件下检查的一项活动。现在是时候把这些点连起来,试图理解一个更大的图景:所有这些相互作用是如何、在哪里、何时发生的……,为什么?研究这些问题也将表明,在健康和疾病中,有多少尚不清楚的细胞过程共同作用于细胞和组织的稳态。
{"title":"Human papillomavirus E6 and E7: What remains?","authors":"Arushi Vats ,&nbsp;Oscar Trejo-Cerro ,&nbsp;Miranda Thomas,&nbsp;Lawrence Banks","doi":"10.1016/j.tvr.2021.200213","DOIUrl":"10.1016/j.tvr.2021.200213","url":null,"abstract":"<div><p>Decades of research on the human papillomavirus oncogenes, E6 and E7, have given us huge amounts of data on their expression, functions and structures. We know much about the very many cellular proteins and pathways that they influence in one way or another. However, much of this information is quite discrete, referring to one activity examined under one condition. It is now time to join the dots to try to understand a larger picture: how, where and when do all these interactions occur... and why? Examining these questions will also show how many of the yet obscure cellular processes work together for cellular and tissue homeostasis in health and disease.</p></div>","PeriodicalId":52381,"journal":{"name":"Tumour Virus Research","volume":"11 ","pages":"Article 200213"},"PeriodicalIF":4.3,"publicationDate":"2021-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.tvr.2021.200213","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25476990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 40
Corrigendum to CINtec PLUS and cobas HPV testing for triaging Canadian women referred to colposcopy with a history of low-grade squamous intraepithelial lesion: Baseline findings [Papillomavirus Res. 10 (2020) 100206] CINtec PLUS和cobas HPV检测用于诊断有低级别鳞状上皮内病变史的加拿大女性阴道镜检查:基线结果[乳头瘤病毒杂志,10 (2020)100206]
IF 4.3 Q1 VIROLOGY Pub Date : 2021-06-01 DOI: 10.1016/j.tvr.2021.200215
Sam Ratnam , Dan Jang , Laura Gilbert , Reza Alaghehbandan , Miranda Schell , Rob Needle , Anne Ecobichon-Morris , Peizhong Peter Wang , Mozibur Rahman , Dustin Costescu , Laurie Elit , George Zahariadis , Max Chernesky
{"title":"Corrigendum to CINtec PLUS and cobas HPV testing for triaging Canadian women referred to colposcopy with a history of low-grade squamous intraepithelial lesion: Baseline findings [Papillomavirus Res. 10 (2020) 100206]","authors":"Sam Ratnam ,&nbsp;Dan Jang ,&nbsp;Laura Gilbert ,&nbsp;Reza Alaghehbandan ,&nbsp;Miranda Schell ,&nbsp;Rob Needle ,&nbsp;Anne Ecobichon-Morris ,&nbsp;Peizhong Peter Wang ,&nbsp;Mozibur Rahman ,&nbsp;Dustin Costescu ,&nbsp;Laurie Elit ,&nbsp;George Zahariadis ,&nbsp;Max Chernesky","doi":"10.1016/j.tvr.2021.200215","DOIUrl":"10.1016/j.tvr.2021.200215","url":null,"abstract":"","PeriodicalId":52381,"journal":{"name":"Tumour Virus Research","volume":"11 ","pages":"Article 200215"},"PeriodicalIF":4.3,"publicationDate":"2021-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.tvr.2021.200215","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25496077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Welcome to Tumour Virus Research 欢迎来到肿瘤病毒研究
IF 4.3 Q1 VIROLOGY Pub Date : 2021-06-01 DOI: 10.1016/j.tvr.2021.200211
Peter L. Stern, Lawrence Banks
{"title":"Welcome to Tumour Virus Research","authors":"Peter L. Stern,&nbsp;Lawrence Banks","doi":"10.1016/j.tvr.2021.200211","DOIUrl":"10.1016/j.tvr.2021.200211","url":null,"abstract":"","PeriodicalId":52381,"journal":{"name":"Tumour Virus Research","volume":"11 ","pages":"Article 200211"},"PeriodicalIF":4.3,"publicationDate":"2021-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.tvr.2021.200211","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25381586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Tumour Virus Research
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1